Forest Inks Deals with Nycomed and AstraZeneca
By Taskin Ahmed
Pharma Deals Review: Vol 2009 Issue 8 (Table of Contents)
Published: 19 Aug-2009
DOI: 10.3833/pdr.v2009.i8.1174 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
With the upcoming patent expiry of its best selling drug, Lexapro® (escitalopram), on the horizon, Forest has paid US$100 M to Nycomed for US rights to the chronic obstructive pulmonary disease (COPD) drug, Daxas® (roflumilast)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS